MSI2 and B-cell non-Hodgkin lymphoma: Specifically, downregulation of MSI2 in primary CLL cells and in three B-cell lines (MEC1, CRL-2261, and Ramos) reduced cell viability, suggesting MSI2 plays a role in CLL-cell and B-cell lymphoma-cell survival.